Cenobamate as an Early Adjunctive Treatment in Drug-Resistant Focal-Onset Seizures: An Observational Cohort Study.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
03 Aug 2024
03 Aug 2024
Historique:
accepted:
14
07
2024
medline:
4
8
2024
pubmed:
4
8
2024
entrez:
3
8
2024
Statut:
aheadofprint
Résumé
Cenobamate (CNB) is a new antiseizure medication (ASM) to treat drug-resistant, focal-onset seizures. Data on its use in early therapy lines are not yet available, and clinicians frequently consider CNB to be a later ASM drug choice. We investigated the efficacy and safety of CNB as an early adjunctive treatment in drug-resistant, focal-onset seizures. The study population were patients with drug-resistant, focal-onset seizures who were initiated with CNB after they did not respond to two or three lifetime ASMs, including all prior and concomitant ASMs. These patients were matched (1:2) by sex, age, and seizure frequency to controls who were initiated with any ASM other than CNB. All participants participated in the Mainz Epilepsy Registry. We evaluated the retention rate after 12 months of CNB and after each new adjunctive ASM in the control group. In addition, seizure freedom and the response rate (reduction of seizure frequency by ≥ 50% from baseline) after 12 months were estimated. We included 231 patients aged 44.4 ± 15.8 years. Of these, 33.3% (n = 77) were on CNB, 19.0% (n = 44) on valproate (VPA), 17.3% (n = 40) on lacosamide (LCS), 16.4% (n = 38) on levetiracetam (LEV), and 13.9% (n = 32) on topiramate (TPM). The highest retention rate after 12 months since the beginning of the early adjunctive therapy was observed on CNB (92.0%), compared with LCS (80.0%), LEV (73.3%), VPA (68.2%), or TPM (62.5%) (p < 0.05). Seizure freedom and response rate were also the best on CNB (19.5% and 71.4%, respectively) compared with other ASMs (8.3% and 52.5%, respectively; p < 0.05). No significant differences in adverse events between CNB and other ASMs were observed. Our study provides evidence that CNB is an effective ASM with a good safety profile in the early therapy lines of drug-resistant, focal-onset seizures. This data should support medical decision making in the management of patients with refractory epilepsy. NCT05267405.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Cenobamate (CNB) is a new antiseizure medication (ASM) to treat drug-resistant, focal-onset seizures. Data on its use in early therapy lines are not yet available, and clinicians frequently consider CNB to be a later ASM drug choice. We investigated the efficacy and safety of CNB as an early adjunctive treatment in drug-resistant, focal-onset seizures.
METHODS
METHODS
The study population were patients with drug-resistant, focal-onset seizures who were initiated with CNB after they did not respond to two or three lifetime ASMs, including all prior and concomitant ASMs. These patients were matched (1:2) by sex, age, and seizure frequency to controls who were initiated with any ASM other than CNB. All participants participated in the Mainz Epilepsy Registry. We evaluated the retention rate after 12 months of CNB and after each new adjunctive ASM in the control group. In addition, seizure freedom and the response rate (reduction of seizure frequency by ≥ 50% from baseline) after 12 months were estimated.
RESULTS
RESULTS
We included 231 patients aged 44.4 ± 15.8 years. Of these, 33.3% (n = 77) were on CNB, 19.0% (n = 44) on valproate (VPA), 17.3% (n = 40) on lacosamide (LCS), 16.4% (n = 38) on levetiracetam (LEV), and 13.9% (n = 32) on topiramate (TPM). The highest retention rate after 12 months since the beginning of the early adjunctive therapy was observed on CNB (92.0%), compared with LCS (80.0%), LEV (73.3%), VPA (68.2%), or TPM (62.5%) (p < 0.05). Seizure freedom and response rate were also the best on CNB (19.5% and 71.4%, respectively) compared with other ASMs (8.3% and 52.5%, respectively; p < 0.05). No significant differences in adverse events between CNB and other ASMs were observed.
CONCLUSIONS
CONCLUSIONS
Our study provides evidence that CNB is an effective ASM with a good safety profile in the early therapy lines of drug-resistant, focal-onset seizures. This data should support medical decision making in the management of patients with refractory epilepsy.
CLINICAL TRIAL ID
BACKGROUND
NCT05267405.
Identifiants
pubmed: 39096467
doi: 10.1007/s40263-024-01109-9
pii: 10.1007/s40263-024-01109-9
doi:
Banques de données
ClinicalTrials.gov
['NCT05267405']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Angelini Pharma
ID : not appicable
Informations de copyright
© 2024. The Author(s).
Références
Schulze-Bonhage A, Hirsch M, Knake S, Kaufmann E, Kegele J, Rademacher M, et al. Focal cortex stimulation with a novel implantable device and antiseizure outcomes in 2 prospective multicenter single-arm trials. JAMA Neurol. 2023;80(6):588–96.
pubmed: 37010826
pmcid: 10071400
doi: 10.1001/jamaneurol.2023.0066
Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77.
pubmed: 19889013
doi: 10.1111/j.1528-1167.2009.02397.x
Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935–63.
pubmed: 34145528
pmcid: 8408078
doi: 10.1007/s40263-021-00827-8
Nakamura M, Cho JH, Shin H, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;15(855):175–82.
doi: 10.1016/j.ejphar.2019.05.007
Perucca E, Bialer M, White HS. New GABA-targeting therapies for the treatment of seizures and epilepsy: I. role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system. CNS Drugs. 2023;37(9):755–79.
pubmed: 37603262
pmcid: 10501955
doi: 10.1007/s40263-023-01027-2
French JA, Chung SS, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142–50.
pubmed: 34254673
pmcid: 8456960
doi: 10.1111/epi.17007
Klein P, Aboumatar S, Brandt C, Dong F, Krauss GL, Mizne S, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989–98.
pubmed: 35705501
pmcid: 9519254
doi: 10.1212/WNL.0000000000200792
Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099–108.
pubmed: 32396252
pmcid: 7317552
doi: 10.1111/epi.16525
Beltrán-Corbellini Á, Romeral-Jiménez M, Mayo P, Sánchez-Miranda Román I, Iruzubieta P, Chico-García JL, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71–7.
pubmed: 37549616
doi: 10.1016/j.seizure.2023.07.026
Villanueva V, Santos-Carrasco D, Cabezudo-García P, Gómez-Ibáñez A, Garcés M, Serrano-Castro P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an Expanded Access Program. Epilepsia Open. 2023;8(3):918–29.
pubmed: 37149853
pmcid: 10472366
doi: 10.1002/epi4.12757
Serrano-Castro PJ, Ramírez-García T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study. CNS Drugs. 2024;38(2):141–51.
pubmed: 38265735
pmcid: 10881647
doi: 10.1007/s40263-024-01063-6
Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522–30.
pubmed: 28276060
doi: 10.1111/epi.13670
Aboumatar S, Ferrari L, Stern S, Wade CT, Weingarten M, Connor GS, et al. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res. 2024;200: 107306.
pubmed: 38340681
doi: 10.1016/j.eplepsyres.2024.107306
Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure. 2007;16(4):296–304.
pubmed: 17267243
doi: 10.1016/j.seizure.2007.01.004
Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol. 2004;3(10):618–21.
pubmed: 15380158
doi: 10.1016/S1474-4422(04)00882-8
Weissinger F, Losch F, Winter Y, Brecht S, Lendemans D, Kockelmann E. Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: results from a German prospective multicenter clinical practice study. Epilepsy Behav. 2019;101(Pt A): 106574.
pubmed: 31678808
doi: 10.1016/j.yebeh.2019.106574
Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav. 2022;126: 108429.
pubmed: 34864380
doi: 10.1016/j.yebeh.2021.108429
Sander JW, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139–49.
pubmed: 34813673
doi: 10.1111/epi.17134
Kwok CS, Johnson EL, Krauss GL. Comparing safety and efficacy of “third-generation” antiepileptic drugs: long-term extension and post-marketing treatment. CNS Drugs. 2017;31(11):959–74.
pubmed: 29204953
doi: 10.1007/s40263-017-0480-6
Chung SS, Hogan RE, Blatt I, Lawson PB, Nguyen H, Clark AM, et al. Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures. Epilepsy Behav. 2016;59:13–20.
pubmed: 27084978
doi: 10.1016/j.yebeh.2016.03.005
Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56(12):1772–4.
pubmed: 11425954
doi: 10.1212/WNL.56.12.1772
Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38–48.
pubmed: 31734103
doi: 10.1016/S1474-4422(19)30399-0
Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311–22.
pubmed: 32409485
pmcid: 7357293
doi: 10.1212/WNL.0000000000009530
Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075–88.
pubmed: 27571159
doi: 10.1016/S1474-4422(16)30158-2
Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Curr. 2017;17(3):180–7.
pubmed: 28684957
pmcid: 5486432
doi: 10.5698/1535-7511.17.3.180
de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008;12(4):540–6.
pubmed: 18280210
doi: 10.1016/j.yebeh.2007.12.019
Gaitatzis A, Johnson AL, Chadwick DW, Shorvon SD, Sander JW. Life expectancy in people with newly diagnosed epilepsy. Brain. 2004;127(Pt 11):2427–32.
pubmed: 15371287
doi: 10.1093/brain/awh267
Winter Y, Daneshkhah N, Galland N, Kotulla I, Krüger A, Groppa S. Health-related quality of life in patients with poststroke epilepsy. Epilepsy Behav. 2018;80:303–6.
pubmed: 29429905
doi: 10.1016/j.yebeh.2017.12.037
Winter Y, Uphaus T, Sandner K, Klimpe S, Stuckrad-Barre SV, Groppa S. Efficacy and safety of antiseizure medication in post-stroke epilepsy. Seizure. 2022;100:109–14.
pubmed: 35834881
doi: 10.1016/j.seizure.2022.07.003
Sinha N, Peternell N, Schroeder GM, de Tisi J, Vos SB, Winston GP, et al. Focal to bilateral tonic-clonic seizures are associated with widespread network abnormality in temporal lobe epilepsy. Epilepsia. 2021;62(3):729–41.
pubmed: 33476430
pmcid: 8600951
doi: 10.1111/epi.16819
Bell GS, de Tisi J, Gonzalez-Fraile JC, Peacock JL, McEvoy AW, Harkness WFJ, et al. Factors affecting seizure outcome after epilepsy surgery: an observational series. J Neurol Neurosurg Psychiatry. 2017;88(11):933–40.
pubmed: 28870986
doi: 10.1136/jnnp-2017-316211
Aboumatar S, Biton V, Wechsler R, Ferrari L, Rosenfeld WE. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. Epilepsy Res. 2022;186: 107014.
pubmed: 36063589
doi: 10.1016/j.eplepsyres.2022.107014
Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172: 106592.
pubmed: 33662894
doi: 10.1016/j.eplepsyres.2021.106592
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–86.
pubmed: 29279892
doi: 10.1001/jamaneurol.2017.3949
Löscher W, Sills GJ, White HS. The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ? Epilepsia. 2021;62(3):596–614.
pubmed: 33580520
doi: 10.1111/epi.16832
Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–44.
pubmed: 17386054
doi: 10.1111/j.1528-1167.2007.01041.x
Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609–18.
pubmed: 33993416
doi: 10.1007/s40263-021-00819-8
Wang XQ, Lv B, Wang HF, Zhang X, Yu SY, Huang XS, et al. Lamotrigine induced DIHS/DRESS: manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg. 2015;138:1–7.
pubmed: 26209753
doi: 10.1016/j.clineuro.2015.07.008
Winter Y, Sandner K, Glaser M, Ciolac D, Sauer V, Ziebart A, et al. Synergistic effects of vagus nerve stimulation and antiseizure medication. J Neurol. 2023;270(10):4978–84.
pubmed: 37368131
pmcid: 10511567
doi: 10.1007/s00415-023-11825-9
Winter Y, Sandner K, Vieth T, Groppa S. Eslicarbazepine acetate for the treatment of status epilepticus. Epileptic Disord. 2023;25(2):142–9.
pubmed: 37358909
doi: 10.1002/epd2.20004
Sáenz-Farret M, Tijssen MAJ, Eliashiv D, Fisher RS, Sethi K, Fasano A. Antiseizure drugs and movement disorders. CNS Drugs. 2022;36(8):859–76.
pubmed: 35861924
doi: 10.1007/s40263-022-00937-x
Winter Y, Sandner K, Vieth TL, Melzer N, Klimpe S, Meuth SG, et al. Eslicarbazepine acetate as adjunctive therapy for primary generalized tonic-clonic seizures in adults: a prospective observational study. CNS Drugs. 2022;36(10):1113–9.
pubmed: 36178588
pmcid: 9550753
doi: 10.1007/s40263-022-00954-w
Brodie MJ. Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide. Curr Neurol Neurosci Rep. 2016;16(9):82.
pubmed: 27443649
doi: 10.1007/s11910-016-0678-x